SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go?
PFE 25.82+0.2%Dec 11 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BigKNY3 who wrote (4284)7/13/1998 3:55:00 PM
From: Anthony Wong  Read Replies (1) of 9523
 
Pfizer, Warner-Lambert Get More Approvals For Lipitor
July 13, 1998 3:35 PM

WASHINGTON (Dow Jones)--Lipitor, which Pfizer
Inc. (PFE) and Warner-Lambert Co. (WLA)
co-market, received two additional approvals from the
U.S. Food and Drug Administration.

At the end of 1996, the FDA originally cleared the drug
as a cholesterol-lowering therapy.

Friday, the FDA granted expanded approval for the
drug to be used with diet changes by patients with high
triglyceride, or fat levels.

Lipitor was also cleared for marketing as a treatment for
patients who haven't responded adequately to dietary
changes in treating primary dysbetalipoproteinemia,
which causes people to have extremely high amounts of
cholesterol and other fats in their blood streams.

As of June, Lipitor had captured almost 40% of the
market for statins, a class of cholesterol-lowering drugs.

Warner-Lambert reported in its last quarterly earnings
report that Lipitor had sales of $378 million for the
three-month period.
-Otesa Middleton 202-862-6654
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext